Ardelyx, Inc (ARDX) PT Raised to $7 at Citi, 'Granting of Appeal Unprecedented'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Ardelyx, Inc (ARDX) PT Raised to $7 at Citi, 'Granting of Appeal Unprecedented'

Ardelyx, Inc (ARDX) PT Raised to $3 at Cantor Fitzgerald

December 29, 2022 8:01 AM EST

Cantor Fitzgerald analyst Louis Chen raised the price target on Ardelyx, Inc (NASDAQ: ARDX) to $3.00 (from $1.60) while maintaining a Neutral rating.... More

Ardelyx (ARDX) Granted FDA Appeal for XPHOZAH

December 29, 2022 7:00 AM EST

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research of the U.S. Food and Drug Administration (FDA) granted the appeal to the Complete Response Letter (CRL) for the New Drug Application (NDA) for XPHOZAH.

In the response letter, OND directed the FDA's Division of Cardiology and Nephrology (DCN) to work with Ardelyx to develop an appropriate label. Ardelyx believes that... More